Paper Review Records
All Paper Review Records
18 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
72
days
Population Reference Data in the Molecular Diagnosis of Pathogenic CAPN3 Variants: Contextual Evidence and Interpretive Limits
Authors
Meghan H. Carr; Ehab Y. Harahsheh; Shaymaa Shurrab; Bukola A. Olarewaju; Mayowa A. OsundijiShow moreShow less
Affiliations
1. Omics Curation Ltd., Hayes, UK; 2. Department of Neurology, Mayo Clinic, Phoenix, USA; 3. Division of Genetics/Metabolics, McMaster University, Hamilton, Canada; 4. School of Science and Engineering, University of Dundee, Dundee, UK; 5. Department of Clinical Genomics, Mayo Clinic, Phoenix, USA; 6. Prism Biomedical Consulting, Niagara Falls, CanadaShow moreShow less
35
days
Orca-T: First Approval
Authors
Hannah A. BlairShow moreShow less
Affiliations
1. Springer Nature, Auckland, New ZealandShow moreShow less
82
days
Rapid Ex Vivo Visualization of Laryngeal Tumors Using a Sprayable pH-Activatable Fluorophore
Authors
Daan G. J. Linders; Sebastiaan W. R. Dalmeijer; Bo E. Zweedijk; Hamed Abbasi; Danielle Boldewijn; Sjors A. Koppes; Bernd Kremer; Jacobus Burggraaf; Denise E. Hilling; Joost R. van der Vorst; Jinhui Ser; Satoshi Kashiwagi; Maged Henary; Jeroen C. Jansen; Alexander L. Vahrmeijer; Hak Soo Choi; Stijn KeereweerShow moreShow less
Affiliations
1. Department of Otorhinolaryngology and Head and Neck Surgery, Leiden University Medical Center, Leiden, The Netherlands; 2. Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands; 3. Department of Otorhinolaryngology and Head and Neck Surgery, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands; 4. Department of Pathology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands; 5. Centre for Human Drug Research, Leiden, The Netherlands; 6. Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands; 7. Department of Surgical Oncology and Gastrointestinal Surgery, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands; 8. Gordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, USA; 9. Center for Inflammation Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, USA; 10. Department of Chemistry, Center of Diagnostics and Therapeutics, Georgia State University, Atlanta, USAShow moreShow less
90
days
Bridging Biomarker Testing to Biomarker-Driven Targeted Therapy: Real-World ESR1 Mutation Testing Patterns and Prevalence in ER+, HER2− Metastatic Breast Cancer
Authors
Chi-Yin Liao; Jincy John; Precious Anyanwu; Manali A. Bhave; Francois-Clement Bidard; Tyler Marquart; Francisco Sapunar; Aarti Chawla; Lindsay A. WilliamsShow moreShow less
Affiliations
1. Eli Lilly and Company, Indianapolis, USA; 2. Winship Cancer Institute of Emory University, Atlanta, USA; 3. Institut Curie, Paris, FranceShow moreShow less
19
days
Anbalcabtagene Autoleucel: First Approval
Authors
Arnold LeeShow moreShow less
Affiliations
1. Springer Nature, Auckland 0754, New ZealandShow moreShow less
80
days
Development of a Point-of-Care Recombinase Polymerase Amplification Assay for Detection of Neisseria gonorrhoeae and Ceftriaxone-Resistance Associated penA Allele 60.001
Authors
Xia Sun; Ying Fu; Yi Liu; Qiongyao Liu; Luxia Chen; Jiang Zhu; Xu’ai Lin; Hao Cheng; Stijn van der VeenShow moreShow less
Affiliations
1. Department of Infectious Diseases of the Second Affiliated Hospital of Zhejiang University School of Medicine, Department of Microbiology, School of Medicine, Zhejiang University, Hangzhou, China; 2. Zhejiang University-University of Edinburgh Institute, School of Medicine, Zhejiang University, Haining, China; 3. Department of Clinical Laboratory, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China; 4. Amp-Future Biotech, Changzhou, China; 5. Department of Dermatology and Venereology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China; 6. State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, ChinaShow moreShow less
FAQ
How long does Molecular Diagnosis & Therapy take to review a manuscript?
As of 2026-11-18, CrushSCI has 18 complete review records for Molecular Diagnosis & Therapy. The fastest paper went from submission to acceptance in 19 days (Anbalcabtagene Autoleucel: First Approval, received 2026-07-10, accepted 2026-07-29); the slowest took 120 days. The average is 68.8 days and the median is 73.5 days.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
